Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

In all models, plasma total cholesterol and the use of lipid-lowering medication were negatively and positively associated with plasma α: and γ-tocopherol, respectively, while 25-hydroxyvitamin D was positively and negatively associated with plasma α: and γ-tocopherol, respectively.Univariable and multivariable associations of urinary α: and γ-CEHC normalized for creatinine and 24 h urinary α: and γ-CEHC excretions with plasma α: and γ-tocopherol levels separatelyPlasma α-tocopherol level (µmol/mmol)bPlasma γ-tocopherol level (µmol/mmol)bStandardized beta (95% CI)PStandardized beta (95% CI)PUnivariable α-CEHC (µmol/mmol)a0.07 (0.02, 0.12)0.01−0.05 (−0.10, 0.00)0.07Univariable γ-CEHC (µmol/mmol)a0.06 (0.02, 0.12)0.010.04 (−0.01, 0.10)0.1Multivariable α-CEHC (µmol/mmol)a0.06 (0.01, 0.11)0.01−0.04 (−0.09, 0.01)0.1 25-hydroxyvitamin D0.09 (0.04, 0.14) < 0.001−0.03 (−0.08, 0.02)0.1 γ-CEHC (µmol/mmol)a0.04 (−0.01,0.10)0.10.04 (−0.01, 0.09)0.09 Age0.01 (−0.04, 0.06)0.7−0.07 (−0.12,−0.01)0.01 Male−0.01 (−0.13, 0.12)0.8−0.12 (−0.24, 0.01)0.06 BSA−0.08 (−0.14,−0.02)0.010.03 (−0.03, 0.10)0.3 Smoking Former0.05 (−0.06, 0.16)0.50.10 (−0.01, 0.21)0.04 Current−0.13 (−0.30,−0.04)0.10.03 (−0.14, 0.19)0.6 NeverRefRef SES0.10 (0.00, 0.21)0.05−0.02 (−0.12, 0.09)0.7 Total cholesterol−0.16 (−0.22,−0.10) < 0.001−0.14 (−0.20,−0.08) < 0.001 Lipid-lowering medication0.25 (0.11, 0.38) < 0.0010.20 (0.07, 0.34)0.007Univariable α-CEHC (µmol/24 h)0.06 (0.01, 0.11)0.02−0.04 (−0.09, 0.01)0.1Univariable γ-CEHC (µmol/24 h)0.07 (0.02, 0.12)0.0080.05 (0.01, 0.10)0.08Multivariable α-CEHC (µmol/24 h)0.06 (0.01, 0.11)0.02−0.04 (−0.09, 0.01)0.1 25-Hydroxyvitamin D0.11 (0.06, 0.16) < 0.001−0.02 (−0.07, 0.03)0.1 γ-CEHC (µmol/24 h)0.05 (−0.01,0.10)0.060.04 (−0.01, 0.09)0.1 Age0.01 (−0.04, 0.06)0.8−0.07 (−0.12,−0.02)0.01 Male−0.03 (−0.16, 0.09)0.6−0.12 (−0.24, 0.01)0.06 BSA−0.09 (−0.15, -0.02)0.0040.03 (−0.04, 0.09)0.3 Smoking Former0.05 (−0.06, 0.16)0.40.11 (0.01, 0.22)0.04 Current−0.13 (−0.30, 0.04)0.10.02 (−0.15, 0.19)0.6 NeverRefRef SES0.11 (0.01, 0.21)0.04−0.04 (−0.14, 0.07)0.7 Total cholesterol−0.16 (−0.22,−0.10) < 0.001−0.13 (−0.19,−0.07) < 0.001 Lipid-lowering medication0.24 (0.11 to 0.38) < 0.0010.19 (0.06 to 0.33)0.007Univariable α + γ-CEHC (µmol/24 h)0.08 (0.03, 0.13)0.0020.0001 (−0.05, 0.05)0.8Multivariable α + γ-CEHC (µmol/24 h)0.07 (0.02, 0.12)0.0070.002 (−0.05, 0.05)0.9 25-Hydroxyvitamin D0.10 (0.05, 0.15) < 0.001−0.04 (−0.09, 0.01)0.09 Age0.01 (−0.04, 0.06)0.7−0.07 (−0.12,−0.02)0.01 Male−0.03 (−0.16, 0.09)0.6−0.12 (−0.24, 0.01)0.06 BSA−0.09 (−0.15,−0.03)0.0050.03 (−0.03, 0.09)0.3 Smoking Former0.03 (−0.08, 0.14)0.50.12 (0.01, 0.23)0.04 Current−0.14 (−0.31, 0.03)0.10.04 (−0.12, 0.21)0.6 NeverRefRef SES0.10 (0.01,0.20)0.05−0.02 (−0.12, 0.08)0.7 TC−0.16 (−0.22,−0.10) < 0.001−0.14 (−0.20,−0.09) < 0.001 Lipid-lowering medication0.25 (0.12 to 0.39) < 0.0010.19 (0.05, 0.32)0.007CEHC carboxyethyl hydroxychroman, BSA body surface area, SES socioeconomic status, TC total cholesterolaNormalized for urinary creatininebNormalized for total plasma lipids

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The Lifelines Cohort Study is an ongoing observational three-generation population-based follow-up study that aims to investigate the health and health-related behaviors in the process of aging.

Source: Methods.

In short, the first group of participants was recruited from their local general practitioners.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Associations of 24 h urinary excretions of α: and γ-carboxyethyl hydroxychroman with plasma α: and γ-tocopherol and dietary vitamin E intake in older adults: the Lifelines-MINUTHE Study

Cohort study · European Journal of Nutrition · 2022

Original publication title

Associations of 24 h urinary excretions of α: and γ-carboxyethyl hydroxychroman with plasma α: and γ-tocopherol and dietary vitamin E intake in older adults: the Lifelines-MINUTHE Study

Yinjie Zhu; Jan Frank; Ineke J. Riphagen; Isidor Minović; Michel J. Vos; Manfred L. Eggersdorfer; Gerjan J. Navis; Stephan J. L. Bakker

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Our study confirmed our hypothesis that 24 h urinary α: and γ-CEHC excretions would be a better marker for dietary vitamin E intake than urinary α: and γ-CEHC/creatinine ratios. Considering that both 24 h urinary α: and γ-CEHC excretions and α: and γ-CEHC/creatinine ratios were also associated with plasma α-tocopherol status, we suggest that 24 h urinary α: and γ-CEHC excretions could be used to assess overall vitamin E status.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

We aimed to (1) investigate the associations of urinary α: and γ-CEHC/creatinine ratios and 24 h urinary excretions of α: and γ-CEHC with plasma α: and γ-tocopherol, respectively; (2) investigate the associations of urinary α: and γ-CEHC/creatinine ratios and 24 h urinary excretions of α: and γ-CEHC with dietary vitamin E intake, and we hypothesize that 24 h urinary excretions of α: and γ-CEHC will better correlate with vitamin E intake than urinary α: and γ-CEHC/creatinine ratios.

Source: Objectives

Abstract: Design

24 h Urine and plasma samples were collected from 1519 participants (60 to 75 years, male: 50%) included in the Lifelines-MINUTHE Study for the assessments of urinary α: and γ-CEHC/creatinine ratios and 24 h urinary excretions of α: and γ-CEHC, and plasma α: and γ-tocopherol. Among those participants, dietary vitamin E intake data from 387 participants were available from an externally validated Flower-Food Frequency Questionnaire (FFQ). The associations of plasma α: and γ-tocopherol, dietary vitamin E intake, with urinary α: and γ-CEHC were assessed using multivariate linear regressions.

Source: Design

Abstract: Results

24 h Urinary excretion of α-CEHC (median (IQR): 0.9 (0.3 to 2.4) µmol) was less than that of γ-CEHC (median (IQR): 1.5 (0.5 to 3.5) µmol). After adjustment for covariates, we found that 24 h urinary α-CEHC excretion and urinary α-CEHC/creatinine ratio were both positively associated with plasma α-tocopherol (std.beta: 0.06, p = 0.02; std.beta: 0.06, p = 0.01, respectively). Furthermore, the sum of 24 h urinary α: and γ-CEHC excretions was positively associated with dietary vitamin E intake (std.beta: 0.08; p = 0.03), whereas there was no relation between urinary α: and γ-CEHC/creatinine ratios and vitamin E intake.

No association was observed neither between plasma α: and γ-tocopherol and dietary vitamin E intake, nor between urinary γ-CEHC and plasma γ-tocopherol.

Source: Results

Abstract: Conclusion

Our study confirmed our hypothesis that 24 h urinary α: and γ-CEHC excretions would be a better marker for dietary vitamin E intake than urinary α: and γ-CEHC/creatinine ratios. Considering that both 24 h urinary α: and γ-CEHC excretions and α: and γ-CEHC/creatinine ratios were also associated with plasma α-tocopherol status, we suggest that 24 h urinary α: and γ-CEHC excretions could be used to assess overall vitamin E status.

Source: Conclusion
Authors’ abstract

Background

Urinary metabolites of vitamin E, i.e., α: and γ-carboxyethyl hydroxychroman (α: and γ-CEHC), have gained increasing attention and have been proposed as novel biomarkers of vitamin E intake and status. However, there are insufficient data on the relationship of plasma α-tocopherol and γ-tocopherol and dietary vitamin E intake with 24 h urinary excretions of α: and γ-CEHC.

Objectives

We aimed to (1) investigate the associations of urinary α: and γ-CEHC/creatinine ratios and 24 h urinary excretions of α: and γ-CEHC with plasma α: and γ-tocopherol, respectively; (2) investigate the associations of urinary α: and γ-CEHC/creatinine ratios and 24 h urinary excretions of α: and γ-CEHC with dietary vitamin E intake, and we hypothesize that 24 h urinary excretions of α: and γ-CEHC will better correlate with vitamin E intake than urinary α: and γ-CEHC/creatinine ratios.

Design

24 h Urine and plasma samples were collected from 1519 participants (60 to 75 years, male: 50%) included in the Lifelines-MINUTHE Study for the assessments of urinary α: and γ-CEHC/creatinine ratios and 24 h urinary excretions of α: and γ-CEHC, and plasma α: and γ-tocopherol. Among those participants, dietary vitamin E intake data from 387 participants were available from an externally validated Flower-Food Frequency Questionnaire (FFQ). The associations of plasma α: and γ-tocopherol, dietary vitamin E intake, with urinary α: and γ-CEHC were assessed using multivariate linear regressions.

Results

24 h Urinary excretion of α-CEHC (median (IQR): 0.9 (0.3 to 2.4) µmol) was less than that of γ-CEHC (median (IQR): 1.5 (0.5 to 3.5) µmol). After adjustment for covariates, we found that 24 h urinary α-CEHC excretion and urinary α-CEHC/creatinine ratio were both positively associated with plasma α-tocopherol (std.beta: 0.06, p = 0.02; std.beta: 0.06, p = 0.01, respectively). Furthermore, the sum of 24 h urinary α: and γ-CEHC excretions was positively associated with dietary vitamin E intake (std.beta: 0.08; p = 0.03), whereas there was no relation between urinary α: and γ-CEHC/creatinine ratios and vitamin E intake.

No association was observed neither between plasma α: and γ-tocopherol and dietary vitamin E intake, nor between urinary γ-CEHC and plasma γ-tocopherol.

Conclusion

Our study confirmed our hypothesis that 24 h urinary α: and γ-CEHC excretions would be a better marker for dietary vitamin E intake than urinary α: and γ-CEHC/creatinine ratios. Considering that both 24 h urinary α: and γ-CEHC excretions and α: and γ-CEHC/creatinine ratios were also associated with plasma α-tocopherol status, we suggest that 24 h urinary α: and γ-CEHC excretions could be used to assess overall vitamin E status.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00394-022-02918-8.

Publication and source details

Original title: Associations of 24 h urinary excretions of α: and γ-carboxyethyl hydroxychroman with plasma α: and γ-tocopherol and dietary vitamin E intake in older adults: the Lifelines-MINUTHE Study

Yinjie Zhu; Jan Frank; Ineke J. Riphagen; Isidor Minović; Michel J. Vos; Manfred L. Eggersdorfer; Gerjan J. Navis; Stephan J. L. Bakker

European Journal of Nutrition · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T08:47:58.448682+00:00

DOI: 10.1007/s00394-022-02918-8 · PMC9464128